MN HF3054

340B covered entities must report annually by April 1 to the commissioner on drug acquisition costs, payments received broken down by payer type (commercial insurance, Medical Assistance, MinnesotaCare, Medicare), contract pharmacy payments, and detailed internal administrative expenses

Hospitals participating in the 340B program must additionally report data at the national drug code level for their 50 most frequently dispensed or administered drugs

Drug manufacturers must report price increase information for brand name drugs with increases of 10% or more over 12 months or 16% or more over 24 months when the drug costs $100+ for a 30-day supply, including new requirements to disclose units sold, rebates accrued, and the year the drug was introduced to market

The commissioner must publicly post lists of prescription drugs and reporting entities subject to transparency requirements, with drug-specific information aggregated to protect non-manufacturer entity identities

Reporting entity registration requirements are delayed from January 1, 2024 to January 1, 2026, and notifications to report must now specify the reporting period for which data must be provided